Abstract
Solriamfetol is a novel FDA approved enantiopure drug used for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea. Only the active R-enantiomer is marketed, therefore, a method to determine the chiral purity is essential. Chiral separation of solriamfetol was performed by HPLC using polysaccharide-type chiral stationary phases in polar organic mode and described for the first time. Seven different polysaccharide-based chiral columns (Lux Amylose-1, Lux i-Amylose-1, Lux Amylose-2, Lux Cellulose-1, Lux Cellulose-2, Lux Cellulose-3 and Lux Cellulose-4) were employed for the separation of enantiomers using polar organic mode, with mobile phases consisting of 0.15% diethylamine in methanol (MeOH), 2-propanol (IPA) or acetonitrile (ACN). During the screening phase, the best results (Rs> 5, in less than 10 min) was obtained on a Lux Amylose-1 column with 0.15% diethylamine in methanol with an ideal elution order (the distomer eluted before the R-enantiomer). The effects of binary mobile phases on the resolutions and retention factors were also investigated containing different percentages of MeOH:ACN and MeOH:IPA. Using optimized parameters (Lux Amylose-1 column with 0.05% diethylamine in MeOH with 0.6 mL/min flow rate at 20 °C) high enantioresolution (Rs = 5.3) was achieved within 6 min. Thermodynamic analysis was performed and revealed an enthalpy-driven enantioseparation. The developed, isocratic HPLC method was validated according to current ICH guidelines and proved to be reliable, linear, precise and accurate for the determination of 0.1% S-enantiomer as a chiral impurity in R-solriamfetol.
References
Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y (2019) Ann Neurol 85:359–370
Food and Drug Administration, Center for Drug Evaluation and Research, Application number 211230Orig1s000, 21230Orig2s000, Other review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211230Orig1Orig2s000OtherR.pdf. Accessed 17 Apr 2020
Zomorodi K, Kankam M, Lu Y (2019) Clin Ther 41:196–204
Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A (2018) J Pharmacol Exp Ther 366:367–376
Scriba G (2019) Trends Analyt Chem 120:115639
Chankvetadze B (2020) Trends Analyt Chem 122:115709
Ates H, Younes AA, Mangelings D, Vander Heyden Y (2013) J Pharm Biomed Anal 74:1–13
Chankvetadze B, Kartozia I, Yamamoto C, Okamoto Y (2002) J Pharm Biomed Anal 27:467–478
Choi YM, Kim M (2005) U.S. Patent Application No. 10/680,979
Ferencz E, Kovács B, Boda F, Foroughbakhshfasaei M, Kelemen ÉK, Tóth G, Szabó ZI (2020) J Pharm Biomed Anal 177:112851
Matarashvili I, Shvangiradze I, Chankvetadze L, Sidamonidze S, Takaishvili N, Farkas T, Chankvetadze B (2015) J Sep Sci 38:4173–4179
Szabó ZI, Foroughbakhshfasaei M, Gál R, Horváth P, Komjáti B, Noszál B, Tóth G (2018) J Sep Sci 41:1414–1423
Horváth S, Németh G (2018) J Chrom A 1568:149–159
Foroughbakhshfasaei M, Szabó ZI, Tóth G (2018) Chromatographia 81:1613–1621
International Council for Harmonization Guideline Q2(R1), Validation of analytical procedures: text and methodology (2005)
Acknowledgements
This work was supported by the Transylvanian Museum Society and the Faculty of Pharmacy of Semmelweis University (Z.-I. Szabó, G. Tóth) and by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (I. Boldizsár and G. Tóth). The financial support from Semmelweis Innovation Found (STIA‐M‐17 and STIA‐18‐KF) and from Bolyai + New National Excellence Program (grant number: UNKP‐19‐4‐SE‐28) of the Ministry for Innovation and Technology is highly appreciated (G. Tóth). This research was supported by the National Research, Development and Innovation Office, Hungary (NKFIH KH-130401, VEKOP-2.3.3-15-2017-00020), the ELTE Institutional Excellence Program (1783-3/2018/FEKUTSRAT) of the Hungarian Ministry of Human Capacities.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Köteles, I., Foroughbakhshfasaei, M., Dobó, M. et al. Determination of the Enantiomeric Purity of Solriamfetol by High-Performance Liquid Chromatography in Polar Organic Mode Using Polysaccharide-Type Chiral Stationary Phases. Chromatographia 83, 909–913 (2020). https://doi.org/10.1007/s10337-020-03911-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-020-03911-1